Comparative risk of post-acute sequelae following SARS-CoV-2 or influenza virus infection: A retrospective cohort study among United States adults
PLOS Medicine · 2025
DOI: 10.1371/journal.pmed.1004777 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS Medicine, 2025. Verfasst von Joseph A Lewnard und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, University of California, Berkeley, California, United States of America. Hauptthemen laut MEDLINE: COVID-19, Influenza, Human. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Center for Forecasting and Outbreak Analytics.
Abstract (Originalsprache)
Background
Post-acute sequelae (PAS) of SARS-CoV-2 infection are well documented. However, it remains unclear whether such long-term health effects are unique to COVID-19, or also occur following other viral respiratory infections. Methods and findings We undertook a retrospective cohort study of 74,738 COVID-19 cases and 18,790 influenza cases within the Kaiser Permanente Southern California healthcare system diagnosed between 1 September, 2022 and 31 December, 2023. Cases received care for index infections across a spectrum of clinical settings, spanning virtual ( n = 35,835; 38.3%), ambulatory ( n = 26,579; 28.4%), emergency department ( n = 23,388; 25.0%) and inpatient ( n = 7,726; 8.3%) facilities. We compared 180-day risk of PAS-related healthcare utilization among COVID-19 cases and influenza via adjusted hazard ratios (aHRs) weighted to account for cases’ index infection type and follow-up retention. Adjustment models addressed patients’ demographic characteristics, comorbidity profiles, prior healthcare utilization patterns, and index episode severity. Risk of PAS diagnoses in any clinical setting was only modestly higher among COVID-19 cases in comparison to influenza cases within 31−90 days after cases’ initial illness (aHR = 1.04 [95% confidence interval: 0.99, 1.09]; risk difference = 0.6 [–0.1, 1.2] cases per 100 person-months). This difference was attenuated by 91−180 days (aHR = 1.01 [0.97, 1.06]; risk difference = 0.4 [–0.1, 0.9] cases per 100 person-months). However, COVID-19 cases faced higher risk of severe PAS conditions requiring hospitalization (aHR = 1.31 [1.07, 1.59] and 1.24 [1.03, 1.49] within 31−90 and 91−180 days, respectively). This excess risk of severe PAS was concentrated among COVID-19 cases hospitalized during acute-phase illness, and was attenuated among cases who received antiviral treatment, who had up-to-date vaccination status prior to infection, or who did not require inpatient admission for acute-phase illness. As a limitation, analyses included only PAS resulting in healthcare utilization; patient-reported symptoms and quality-of-life measures were not captured.
Conclusions
In this large, real-world cohort, individuals with non-severe acute respiratory illness caused by SARS-CoV-2 experienced only modestly greater risk of PAS in comparison to those whose illness was caused by influenza. However, COVID-19 cases hospitalized for their initial illness experienced greater risk of severe PAS necessitating inpatient care, and this difference persisted through 180 days of follow-up. Our findings challenge assumptions about the uniqueness of post-acute COVID-19 morbidity and suggest the long-term burden of influenza may be underrecognized.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- School of Public Health, University of California, Berkeley, California, United States of America.
- Kaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, United States of America.
- Centers for Disease Control & Prevention, Atlanta, Georgia, United States of America.
- Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, United States of America.
ORCID-Profile: Joseph A Lewnard, Leora R Feldstein, Sharon Saydah, Rulin Hechter, Lina S Sy, Bradley K Ackerson, Sara Y Tartof
Förderung
- Center for Forecasting and Outbreak Analytics
Zitieren
APA
Lewnard, J. A., Malden, D. E., Hong, V., Skela, J., Feldstein, L. R., Saydah, S., Reyes, I. A. C., Hechter, R., Sy, L. S., Ackerson, B. K., & Tartof, S. Y. (2025). Comparative risk of post-acute sequelae following SARS-CoV-2 or influenza virus infection: A retrospective cohort study among United States adults. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004777
Vancouver
Lewnard JA, Malden DE, Hong V, Skela J, Feldstein LR, Saydah S, et al. Comparative risk of post-acute sequelae following SARS-CoV-2 or influenza virus infection: A retrospective cohort study among United States adults. PLOS Medicine. 2025. doi:10.1371/journal.pmed.1004777
BibTeX
@article{Lewnard2025,
author = {Lewnard, Joseph A and Malden, Debbie E and Hong, Vennis and Skela, Jessica and Feldstein, Leora R and Saydah, Sharon and Reyes, Iris Anne C and Hechter, Rulin and Sy, Lina S and Ackerson, Bradley K and Tartof, Sara Y},
title = {Comparative risk of post-acute sequelae following SARS-CoV-2 or influenza virus infection: A retrospective cohort study among United States adults},
journal = {PLOS Medicine},
year = {2025},
doi = {10.1371/journal.pmed.1004777}
}
EUVIMED